Whereas one report noted Nfe2l2 activation via promoter hypomethylation in mouse skin epidermal cells [80], another showed miRNA-mediated inhibition of human NFE2L2 by apigenin, leading to chemosensitization of adriamycin-resistant hepatocellular carcinoma cells [106]. Here, NFE2L2 is linked to hepatocellular carcinoma.